Lipoprotein(a) Management with Levels Less Than 10 mg/dL

Understanding the Risk Context

The median Lipoprotein(a) in the general population is 10-15 mg/dL, meaning a patient with a level less than 10 mg/dL has a lower-than-average level 2
The 75th percentile threshold where cardiovascular risk begins to increase is 30 mg/dL in Caucasian populations 2
The European high-risk threshold is >50 mg/dL, and a patient with a level less than 10 mg/dL is nowhere near this level 1
The American College of Cardiology identifies Lipoprotein(a) ≥125 nmol/L (approximately 50 mg/dL) as a risk-enhancing factor, which does not apply to a patient with a level less than 10 mg/dL 1

For very high-risk patients, the American College of Cardiology recommends targeting LDL-C <1.8 mmol/L (70 mg/dL) or ≥50% reduction from baseline 1, 3
For high-risk patients, the American College of Cardiology recommends targeting LDL-C <2.6 mmol/L (100 mg/dL) or ≥50% reduction from baseline 1, 3
For patients with 2+ risk factors and 10-year CHD risk ≥10%, the American Heart Association recommends targeting LDL-C <130 mg/dL 4

The American College of Cardiology recommends initiating high-intensity statin therapy with atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily 1, 3
The American College of Cardiology recommends adding ezetimibe 10 mg daily if LDL-C remains >100 mg/dL on maximally tolerated statin 1
The American College of Cardiology recommends reserving PCSK9 inhibitors for patients who fail to reach LDL-C goals despite statin + ezetimibe 1, 3

The American College of Cardiology does not recommend more aggressive LDL-C targets beyond standard risk-based goals for patients with Lp(a) <10 mg/dL 1, 3
The American College of Cardiology does not recommend niacin therapy for patients with Lp(a) <10 mg/dL, as niacin's primary role is Lp(a) reduction 3, 2

The American College of Cardiology recommends rechecking lipid panel 4-6 weeks after initiating or adjusting therapy 1, 3
The American College of Cardiology recommends assessing achievement of LDL-C goal based on patient's overall cardiovascular risk category 1
The American College of Cardiology recommends monitoring non-HDL-C with goal <130 mg/dL (3.4 mmol/L) for high-risk patients 1, 3